Claim extract · Listening Library
Perry & Hubbard interviews: research-funding advocacy vs federal Schedule I
LAST REVIEWED 2026-09-22 · POLICY MEDIA · NOT LEGAL ADVICE
High-reach interviews with Rick Perry and W. Bryan Hubbard discuss state research-funding politics and veteran narratives. Catalog for claim-check against primary bills and FDA / Schedule I facts — not as clinical proof.
Policy advocacy mediaFunding ≠ approvalNot legal advice
Listening Library sources (outbound)
jre-2477-perry-hubbard-2026— Joe Rogan Experience #2477 Spotify. Confidence: high.third-wave-305-bryan-hubbard— Third Wave #305 show notes. Confidence: high.
Testable claims extracted (media → primary)
- Claim (media): Texas enacted a large state-backed ibogaine clinical-research program.
Primary (law / agency): Texas SB 2308 bill analysis capitol.texas.gov; UTMB award announcement UTMB news. Label: research funding / trial pathway — not FDA drug approval. - Claim (media): Kentucky’s earlier opioid-settlement ibogaine proposal became lasting treatment access.
Primary / journalism record: Proposal was rejected after leadership change — NPR 2024 coverage and IbogaBase policy desk. - Claim (federal baseline): State research bills erase federal Schedule I status for ibogaine.
Primary: 21 CFR 1308.11 Cornell LII. FAQ: Schedule I vs state bills. - Claim (overclaim): Podcast efficacy percentages or “miracle” framing prove clinical effectiveness.
Verdict: Overstated / media risk — miracle-title literacy + denominators.
Verdict
Useful policy-attention media; pair every funding claim to primary bill text and keep federal Schedule I / non-approval facts explicit. Educational only — not legal advice and not a treatment-seeking guide.